When a Screening Endoscopy Finds a Dark Spot in the Esophagus During Melanoma Follow-Up: The Four Ways That Finding Can Be Read, and How to Prepare Before the Next Clinic Visits

People being treated for melanoma often undergo routine general health screening alongside their scheduled follow-up imaging. When a screening endoscopy reports a dark spot on the esophageal lining and a biopsy is taken, the days spent waiting for the pathology report can feel unusually long. The question in most people's minds compresses into one word: metastasis or not. In the clinic, however, that single question is usually separated into four distinct possibilities, and knowing them in advance makes it much easier to ask useful questions when the results arrive.

First, a lesion that spread from elsewhere. Melanoma can involve lymph nodes, lungs, liver and brain, and it can also involve the gastrointestinal tract. Within the digestive tract, the esophagus is reported far less often than the stomach or small bowel. Describing something as uncommon does not mean impossible; it means the team will not draw a conclusion from an endoscopic image alone, and will read the tissue findings together with whole-body imaging.

Second, a tumour that began in the esophagus itself. Primary mucosal melanoma of the esophagus exists but is rare. One clue pathologists look for is whether atypical melanocytes are present within the surface epithelium itself, and another is how closely the current specimen resembles the earlier skin lesion. Because the starting point of the treatment plan differs depending on which reading applies, this part of the assessment takes time.

Third, pigmentation that is not cancer. The esophagus can appear dark for benign reasons: a benign increase in melanocytes, residual pigment after old bleeding or inflammation, food or medication effects, or pressure marks from the procedure itself. Colour alone cannot separate these from a tumour, which is exactly why tissue is sampled.

Fourth, a result that cannot yet be finalised. If the sample is small or only superficial, the report may be deferred. Amelanotic melanoma, which contains little pigment, may not look dark at all. For these reasons, when melanoma is suspected, routine staining is commonly supplemented by immunohistochemistry using markers such as S100, SOX10, HMB-45 and Melan-A.

When the treating hospital suggests repeating the biopsy, it is usually not because the outside result is distrusted. Re-examining the tissue with the same criteria and the same panel of stains produces a result the team can act on directly. If the first biopsy was done elsewhere, ask early whether the paraffin block or the slides can be transferred along with the written report, since this can shorten the repeat process.

Whole-body imaging answers a different question: is this the only site? PET-CT surveys metabolically active lesions broadly, but it has limits with very small lesions and with distinguishing tumour from inflammation or normal physiological uptake, so it is interpreted together with CT or MRI. The brain is often assessed with dedicated imaging, and blood tests such as LDH may be followed as well. When results are explained, it helps to ask not only what was seen, but what was not seen, and when the next scan is planned.

It is not unusual for earlier tissue sampling to show tumour cells while a later sentinel lymph node specimen shows none. The involved tissue may already have been removed by the diagnostic excision or prior treatment, or the sampled site and section depth may simply differ. These records are used later when treatment direction is decided, so listing each test by date, institution, specimen number and summary result on a single page prevents having to reconstruct the story at every department.

Treatment planning generally divides into local control versus systemic control. The extent, number and location of lesions, the condition of other organs, the response to treatment so far, and overall fitness all shift the balance among endoscopic approaches, surgery, radiotherapy, immunotherapy, and targeted therapy chosen according to genetic alterations. Because these factors differ from person to person, no single approach can be declared better in advance, and a multidisciplinary discussion involving gastroenterology, surgery and medical oncology is often arranged.

If two clinic appointments fall on the same day, preparing in this order keeps the visits focused. Put every biopsy and scan on one page in date order. Record the last two to four weeks of swallowing difficulty, how quickly food passes, chest discomfort, weight change and any black stools. Write short questions in advance: is this metastatic or primary, how extensive would surgery be, what are the alternatives if surgery is not chosen, does current treatment continue, and when is the next scan. Photograph all medications and supplements. Decide who will listen with you, and ask whether recording is permitted.

While waiting, seek prompt medical advice or emergency care rather than waiting for the scheduled date if food or even liquids will not pass, if there is vomiting of blood or black stools, or if sudden severe chest or back pain or fever develops.

This article provides general information only and does not replace individual diagnosis or care. Interpretation of test results and treatment decisions depend on your specific situation, so please discuss them with your own medical team.